Centre Revamps Rashtriya Bal Swasthya Karyakram, Adds Mental Health and NCD Screening

IMT News Desk
IMT News Desk
· 2 min read
India launches RBSK 2.0, revamping Rashtriya Bal Swasthya Karyakram to include mental health screening and NCD detection

The Indian government has overhauled its flagship child health screening programme, Rashtriya Bal Swasthya Karyakram (RBSK), launching RBSK 2.0 with an expanded scope to address rising concerns like mental health issues and non-communicable diseases (NCDs).

Released by the Union Health Ministry at the National Summit on Good Practices and Innovations in Public Healthcare Service Delivery, the updated guidelines extend preventive, promotive, and curative care from birth to 18 years, building on the original “4Ds” framework: defects at birth, diseases, deficiencies, and developmental delays, while incorporating behavioural disorders, lifestyle risks such as diabetes and hypertension, and kidney conditions.

Mobile health teams will intensify screenings at anganwadi centres and schools for broader outreach, supported by digital health cards, real-time data systems, and integrated platforms to track progress and ensure continuity of care. Strengthened referral pathways link community-level detection to facility-based treatment, minimizing dropouts through robust follow-up mechanisms.

This digital focus aligns with India’s broader health tech push, aiming to improve early intervention amid growing child obesity and NCD risks. The revamp responds to emerging challenges like mental health conditions and early NCD indicators, which have surged post-pandemic, positioning RBSK as a comprehensive tool for holistic child wellness up to age 18. Officials expect nationwide implementation to yield better health outcomes by enabling timely referrals and sustained monitoring.

After over a decade, this upgrade marks a proactive shift toward tackling lifestyle diseases in younger populations.

Read Next

India’s first focused health AI Conclave unites doctors and AI experts
Featured Article
July 10, 2026

India’s first focused health AI Conclave unites doctors and AI experts

• Global Healthcare Academy hosts HAI Conclave 2026, India’s first national platform dedicated to Healthcare and Artificial Intelligence • Landmark Bengaluru conference brings together healthcare leaders and AI experts to explore how Artificial Intelligence can make healthcare faster, safer and more accessible while keeping patients at the centre of every decision The inaugural edition of the HAI Conclave […]
Article by: IMT News Desk
Fischer Medical Ventures Highlights NYB.AI Partnership as Platform Showcased at NVIDIA GTC Taiwan 2026
News
July 10, 2026

Fischer Medical Ventures Highlights NYB.AI Partnership as Platform Showcased at NVIDIA GTC Taiwan 2026

Fischer Medical Ventures Limited (FMVL) has announced that its strategic partner, Nanyang Biologics, has achieved a major international milestone with its AI-powered molecular research platform, NYB.AI, being featured in the opening showcase at NVIDIA GTC Taiwan 2026, ahead of the keynote address by NVIDIA Founder and CEO Jensen Huang. The recognition places NYB.AI among a […]
Article by: IMT News Desk
Pharma Q1 Margins Seen Under Pressure Despite Revenue Growth: Goldman Sachs
News
July 10, 2026

Pharma Q1 Margins Seen Under Pressure Despite Revenue Growth: Goldman Sachs

Indian pharmaceutical companies are expected to report healthy revenue growth in the first quarter of FY27, but margins are likely to compress as sector profitability comes under pressure. In a recent preview note, Goldman Sachs said it anticipates around 185 basis points year-on-year margin decline for the sector in the June quarter, driven primarily by […]
Article by: IMT News Desk
Dr Reddy’s Delays Semaglutide Supplies After Active Ingredient Quality Issue
News
July 10, 2026

Dr Reddy’s Delays Semaglutide Supplies After Active Ingredient Quality Issue

Dr Reddy’s Laboratories has announced a delay in commercial supplies of its semaglutide product after certain batches were found to be out of specification due to an issue with the active pharmaceutical ingredient (API) used in the drug. The company said it has initiated an investigation into the root cause and is taking corrective measures […]
Article by: IMT News Desk